American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1151-1157 , December 2008

Phosphatemic Effect of Cinacalcet in Kidney Transplant Recipients With Persistent Hyperparathyroidism

  • Andreas L. Serra, MD

      Affiliations

    • Clinic for Nephrology, University Hospital, Switzerland
    • Zürich Center for Integrative Human Physiology, University of Zürich, Switzerland
    • Corresponding Author InformationAddress correspondence to Andreas L. Serra, MD, Clinic for Nephrology, University Hospital, Rämistrasse 100, 8091 Zürich, Switzerland
    • ,
  • Claudia Wuhrmann, MSc

      Affiliations

    • Zürich Center for Integrative Human Physiology, University of Zürich, Switzerland
    • ,
  • Rudolf P. Wüthrich, MD

      Affiliations

    • Clinic for Nephrology, University Hospital, Switzerland
    • Zürich Center for Integrative Human Physiology, University of Zürich, Switzerland

Received 5 May 2008 ,Accepted 4 August 2008.

References 

  1. Kempson SA, Lotscher M, Kaissling B, et al. Parathyroid hormone action on phosphate transporter mRNA and protein in rat renal proximal tubules. Am J Physiol. 1995;268:F784–F791
  2. Ohkido I, Segawa H, Yanagida R, et al. Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney. Pflugers Arch. 2003;446:106–115
  3. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500–6505
  4. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088–F1095
  5. Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154:93–99
  6. Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004;151:55–60
  7. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–2215
  8. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272–2279
  9. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44:250–256
  10. Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006;104:p23–p32
  11. Evenepoel P, Naesens M, Claes K, et al. Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant. 2007;7:1193–1200
  12. Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: Tertiary ‘hyper-phosphatoninism’?. Kidney Int. 2006;70:1486–1494
  13. Fox J, Lowe SH, Petty BA, et al. NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther. 1999;290:473–479
  14. Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007;22:577–583
  15. Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1315–1319
  16. El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation. 2007;83:546–549
  17. Serra AL, Braun SC, Starke A, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 2008;8:803–810
  18. Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1:323–326
  19. Kruse AE, Eisenberger U, Frey FJ, et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1311–1314
  20. Szczech LA. The impact of calcimimetic agents on the use of different classes of phosphate binders: Results of recent clinical trials. Kidney Int Suppl. 2004;90:S46–S48
  21. Szwarc I, Argiles A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation. 2006;82:675–680
  22. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46:58–67
  23. Geller JL, Khosravi A, Kelly MH, et al. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res. 2007;22:931–937
  24. Isakova T, Gutierrez O, Shah A, et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol. 2008;19:615–623
  25. Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18:2683–2688
  26. Sato T, Tominaga Y, Ueki T, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis. 2004;44:481–487
  27. Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006;91:2055–2061
  28. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760–771
  29. Carpenter TO, Ellis BK, Insogna KL, et al. Fibroblast growth factor 7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab. 2005;90:1012–1020

 Originally published online as doi:10.1053/j.ajkd.2008.08.012 on October 28, 2008.

PII: S0272-6386(08)01304-8

doi: 10.1053/j.ajkd.2008.08.012

American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1151-1157 , December 2008

Article Tools

* Image Usage & Resolution